TG TherapeuticsTGTX -3.28%82 PS Ratio is 13.10 as of Jul. 10, 2026, which is 99% below its 10-year median of 1,258.06. GuruFocus rates TGTX with a GF Score™ of 82/100 and a GF Value™ of $59.12 (Fairly Valued). The stock has 8 warning signs investors should review. Among 930 Biotechnology companies, TG Therapeutics ranks worse than 57.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, TG Therapeutics's share price is $57.12.
TG Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $4.36. Hence, TG Therapeutics's PS Ratio for today is 13.10.
Warning Sign:
TG Therapeutics Inc stock PS Ratio (=13.54) is close to 1-year high of 13.54.
The historical rank and industry rank for TG Therapeutics's PS Ratio or its related term are showing as below:
TGTX'
s PS Ratio Range Over the Past 10 Years
Min: 5.42 Med: 1258.06 Max: 54300
Current: 13.08
During the past 13 years, TG Therapeutics's highest PS Ratio was 54300.00. The lowest was 5.42. And the median was 1258.06.
TGTX's PS Ratio is ranked worse than 57.2% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs TGTX: 13.08
TG Therapeutics Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of TG Therapeutics was 81.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 466.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 404.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 126.20% per year.
During the past 13 years, TG Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 1063.00% per year. The lowest was -20.60% per year. And the median was 44.20% per year.
Back to Basics: PS Ratio
TG Therapeutics (NAS:TGTX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
TG Therapeutics PS Ratio Related Terms
TG Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for TG Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, TG Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TG Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TG Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where TG Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
TG Therapeutics's Share Price of today is $57.12. TG Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
TG Therapeutics (TGTX) has a PS Ratio of 13.10 as of Jul. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TG Therapeutics and its competitors. This is 99% below median its historical median of 1,258.06. Over the past decade, TG Therapeutics' PS Ratio has ranged from 5.42 to 54,300.00. According to the industry distribution chart, TG Therapeutics ranks #532 out of 930 companies in the Biotechnology industry, placing it in the top 57.2%.
Is TG Therapeutics' PS Ratio too high?
TG Therapeutics' current PS Ratio of 13.10 is 99% below median its 10-year median of 1,258.06. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 54,300.00. The Biotechnology industry median PS Ratio is 9.52. TG Therapeutics' value of 13.10 is 37.7% above this industry median. Based on the distribution chart, TG Therapeutics ranks #532 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TG Therapeutics has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' PS Ratio compare to HALO and KYMR?
According to the Biotechnology industry distribution chart, TG Therapeutics ranks #532 out of 930 companies for PS Ratio. This places TG Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.52. TG Therapeutics' value of 13.10 is 37.7% above this benchmark. Historically, TG Therapeutics' own PS Ratio has ranged from 5.42 to 54,300.00 over the past decade. While the company's 10-year median is 1,258.06 vs. the industry median of 9.52, TG Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TG Therapeutics's current PS Ratio of 13.10 is 37.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on TG Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TG Therapeutics's current PS Ratio is 13.10, which is 99% below median its own 10-year median of 1,258.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (TGTX) is currently considered Fairly Valued. The stock's GF Value™ is $59.12, compared to a current price of $57.12 — trading 3.4% below its estimated fair value. The current PS Ratio is 13.10, which is 99% below median its 10-year median of 1,258.06 and 37.7% above the Biotechnology industry median of 9.52. TG Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For TG Therapeutics (TGTX), the current PS Ratio is 13.10 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TG Therapeutics (TGTX) Overvalued in 2026?
Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued.
The current stock price of $57.12 is trading 3.4% below its estimated GF Value™ of $59.12.
GuruFocus considers TG Therapeutics to be Fairly Valued.
Key valuation signals for TGTX:
PS Ratio: 13.10 (99% below median its 10-year median of 1,258.06)
GF Value™: $59.12 vs. price of $57.12 (3.4% below fair value)
Industry Position: 37.7% above the Biotechnology median (#532 of 930)
No single metric tells the full story. See the TGTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
82GF Score
Get the complete analysis for TGTX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TGTX has been successfully added to your 
